Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Express Scripts
Moodys
Colorcon
AstraZeneca

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Meloxicam - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for meloxicam and what is the scope of patent protection?

Meloxicam is the generic ingredient in four branded drugs marketed by Zyla, Avondale Pharms, Tersera Theraps Llc, Anda Repository, Apotex Inc, Aurobindo Pharma, Breckenridge Pharm, Cipla, Cr Double Crane, Dr Reddys Labs Inc, Glenmark Generics, Heritage Pharma, Impax Labs Inc, Lupin Pharms, Mylan, Puracap Pharm, Roxane, Strides Pharma, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, and Boehringer Ingelheim, and is included in twenty-six NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has forty-eight patent family members in thirty-one countries.

There are twenty-two drug master file entries for meloxicam. Forty-five suppliers are listed for this compound. There is one tentative approval for this compound.

Drug Prices for meloxicam

See drug prices for meloxicam

Drug Sales Revenue Trends for meloxicam

See drug sales revenues for meloxicam

Recent Clinical Trials for meloxicam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Axsome Therapeutics, Inc.Phase 3
Rush University Medical CenterPhase 3
Columbia UniversityPhase 4

See all meloxicam clinical trials

Recent Litigation for meloxicam

Identify potential future generic entrants

District Court Litigation
Case NameDate
iCeutica Pty Ltd. v. Novitium Pharma LLC2018-04-20
iCeutica Pty Ltd. v. Teva Pharmaceuticals USA, Inc.2018-04-06
iCeutica Pty Ltd. v. Apotex, Inc.2017-10-31

See all meloxicam litigation

Generic filers with tentative approvals for MELOXICAM
Applicant Application No. Strength Dosage Form
  Start Trial  Start Trial10MGCAPSULE;ORAL
  Start Trial  Start Trial5MGCAPSULE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for meloxicam
Synonyms for meloxicam
(3E)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
(3Z)-2-methyl-3-[[(5-methyl-1,3-thiazol-2-yl)amino]-oxidanyl-methylidene]-1,1-bis(oxidanylidene)-1$l^{6},2-benzothiazin-4-one
(3Z)-3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
(3Z)-3-[hydroxy-[(5-methyl-2-thiazolyl)amino]methylidene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
(E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2,3-dihydro-4H-benzo[e][1,2]thiazin-4-one 1,1-dioxide
1027136-06-6
125M387
133687-22-6
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide
2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methylthiazolyl)-, 1,1-dioxide
3-[hydroxy-[(5-methyl-1,3-thiazol-2-yl)amino]methylidene]-2-methyl-1,1-dioxo-1
3-[hydroxy-[(5-methylthiazol-2-yl)amino]methylene]-2-methyl-1,1-dioxo-1$l^{6},2-benzothiazin-4-one
3-{hydroxy[(5-methyl-1,3-thiazol-2-yl)amino]methylidene}-2-methyl-2,3-dihydro-4H-1,2-benzothiazin-4-one 1,1-dioxide
4-Hydroxy-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
4-hydroxy-2-mehtyl-N-(5-mehtyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[e][1,2]thiazine-3-carboxylic acid (5-methyl-thiazol-2-yl)-amide
4-hydroxy-2-methyl-N-(5-methy-2-thiazolyl)-2H-1,2-benzothiazine-3-caboxamide-1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1?^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-1$l^{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1$l;{6},2-benzothiazine-3-carboxamide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-1,1-dioxo-2H-1lambda6,2-benzothiazine-3-carboxamide
4-Hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazin-3-crboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
4-Hydroxy-2-methyl-N-(5-methylthiazol-2-yl)-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide
71125-38-7
A837087
AB0007297
AB00383033_20
AB00383033-17
AB00383033-18
AB1009494
AC-1325
AC1L1HB1
AC1NQY12
AC1NTUST
AC1Q3XZW
AJ-63405
AK-77454
AKOS000279442
AKOS026749959
ALBB-027268
AN-15016
AN-668/13244001
ANW-57553
Apo-meloxicam
BB_SC-04648
BBL029076
BC200593
BCP11928
BDBM50056998
BG0248
BIDD:GT0726
BSPBio_002257
C-20653
C08169
C14H13N3O4S2
CAS-71125-38-7
CC-30198
CCG-39098
CCRIS 9139
CHEBI:6741
CHEMBL1741042
CHEMBL599
Co Meloxicam
Coxflam
Coxicam
CPD000718800
CS-2247
CTK6C3599
CTK6C3600
D00969
DB00814
Dom-meloxicam
DSSTox_CID_803
DSSTox_GSID_20803
DSSTox_RID_75796
DTXSID1020803
EN300-52507
ETI-511
F2173-0387
FT-0082769
FT-0628193
Gen-meloxicam
GTPL7220
HMS1922D19
HMS2089B18
HMS2096I19
HMS2234P07
HMS2236C09
HMS3259H06
HMS3372C13
HMS3372P18
HMS3655K06
HMS3713I19
HSCI1_000045
HSDB 7741
HY-B0261
I06-0490
J10218
KB-242264
KBio2_002113
KBio2_004681
KBio2_007249
KBio3_001477
KBioGR_001234
KBioSS_002113
KS-00000JN4
KS-1084
Lopac0_000766
LS-40538
M1959
MCULE-4138373089
Melonex
Meloxicam (JAN/USAN/INN)
Meloxicam (Mobic)
Meloxicam [USAN:BAN:INN]
Meloxicam [USAN:USP:INN:BAN]
Meloxicam 1.0 mg/ml in Dimethyl Sulfoxide
Meloxicam, 99-101%
Meloxicam,(S)
Meloxicamum
Meloxicamum [Latin]
Meloxivet
Metacam
MFCD00868752
miloxicam
MLS000028587
MLS001304725
MLS001306413
MLS006011422
Mobec
Mobic
Mobic (TN)
Mobicox
MolPort-002-885-839
Movalis
Movatec
MXM
N-1539
NC00698
NCGC00018248-01
NCGC00018248-02
NCGC00018248-03
NCGC00018248-04
NCGC00018248-05
NCGC00018248-06
NCGC00018248-07
NCGC00018248-08
NCGC00022924-03
NCGC00022924-04
NCGC00256316-01
NCGC00259238-01
NCGC00263878-02
Novo-meloxicam
Opera_ID_2
Parocin
PHL-meloxicam
PMS-meloxicam
R3928
Ratio-meloxicam
Revmoksikam
RTR-031220
s1734
SAM002589991
SC-12165
SCHEMBL33369
SCHEMBL3576
SCHEMBL713100
SMP2_000133
SMR000058994
SMR000718800
SPBio_000902
Spectrum_001633
SPECTRUM1504150
Spectrum2_000941
Spectrum3_000649
Spectrum4_000787
Spectrum5_001813
SR-01000003132-10
ST24023559
STK620505
SW219562-1
Tenaron
TL8005001
Tox21_111734
Tox21_111734_1
Tox21_113192
Tox21_201689
Tox21_302756
UH-AC 62XX
UHAC-62XX
UNII-VG2QF83CGL
VG2QF83CGL
Vivlodex
Z1695493323
ZINC103620661
ZINC13129998
ZRVUJXDFFKFLMG-UHFFFAOYSA-N
ZX-AN025777
Paragraph IV (Patent) Challenges for MELOXICAM
Tradename Dosage Ingredient NDA Submissiondate
VIVLODEX CAPSULE;ORAL meloxicam 207233 2017-01-09
MOBIC SUSPENSION;ORAL meloxicam 021530 2009-12-17

US Patents and Regulatory Information for meloxicam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin Pharms MELOXICAM meloxicam TABLET;ORAL 077944-001 Jul 19, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-002 Aug 23, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Yung Shin Pharm MELOXICAM meloxicam TABLET;ORAL 077918-002 Dec 7, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Mylan MELOXICAM meloxicam TABLET;ORAL 077934-001 Jul 20, 2006 DISCN No No   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-001 Apr 13, 2000 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glenmark Generics MELOXICAM meloxicam TABLET;ORAL 077932-002 Jul 19, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
Cipla MELOXICAM meloxicam TABLET;ORAL 077929-002 Jul 19, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Harvard Business School
Colorcon
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.